METHOD FOR ASSESSING THE SUSCEPTIBILITY OF A HUMAN INDIVIDUAL SUFFERING FROM A PSYCHIATRIC OR NEUROLOGICAL DISORDER TO NEUROMODULATION TREATMENT
Method for assessing the susceptibility of a human individual suffering from a psychiatric or neurological disorder, in particular with depressed mood as a predominant feature, to neuromodulation treatment, in particular repetitive Transcranial Magnetic Stimulation (rTMS), the method comprising: a) Providing a dataset comprising electroencephalographic (EEG) activity and Event Related Potentials (ERP) data of said human individual; b) Assessing the susceptibility of said human individual to neuromodulation treatment based on said dataset.
1 - 19 . (canceled)
20 . A negative susceptibility predictor for a neuromodulation treatment comprising an electroencephalographic (EEG) dataset, wherein said predictor is selected from the group consisting of an increased event related potential amplitude (ERP), increased power of slow EEG, increased power in the delta range, increased power in the theta range and low alpha peak frequency as compared to a control EEG dataset.
21 . The negative susceptibility predictor of claim 20 , wherein said EEG dataset further comprises EEG data selected from the group consisting of paroxysmal EEG data, neurological problem EEG data, and epileptic EEG data.
22 . The negative susceptibility predictor of claim 20 , wherein said event related potential amplitude comprises a P300 ERP amplitude.
23 . The negative susceptibility predictor of claim 22 , wherein said increased P300 ERP amplitude is larger than 15 μV.
24 . The negative susceptibility predictor of claim 20 , wherein said increased power of delta or theta slow EEG exceeds 70 μV.
25 . The negative susceptibility predictor of claim 20 , wherein said low alpha peak frequency is lower than 10 Hz.
26 . The negative susceptibility predictor of claim 20 , wherein said EEG dataset is measured from a location selected from the group consisting of F3, Fz, F4, Cz and Pz.
27 . The negative susceptibility predictor of claim 20 , wherein said P300 event related potential comprises a P300 infrequent event amplitude.
28 . The negative susceptibility predictor of claim 20 , wherein said neuromodulation treatment is selected from the group consisting of transcranial magnetic stimulation, transcranial direct current stimulation, deep-brain stimulation, and neurofeedback.
29 . The negative susceptibility predictor of claim 20 , wherein said neuromodulation treatment predicts an unfavorable treatment response in a patient with a psychiatric complaint selected from the group consisting of a major depressive disorder, bipolar disorder, dysthymia, and a depressive mood disorder.
30 . A positive susceptibility predictor for a neuromodulation treatment comprising an electroencephalographic (EEG) dataset, wherein said predictor is selected from the group consisting of increased alpha frontal fast EEG power, increased beta frontal fast EEG power and increased beta EEG power as compared to a control EEG dataset.
31 . The positive susceptibility predictor of claim 30 , wherein said increased alpha frontal fast EEG power is higher than 30 μV.
32 . The positive susceptibility predictor of claim 30 , wherein said increased beta frontal fast EEG power is higher than 30 μV.
33 . The positive susceptibility predictor of claim 30 , wherein said increased beta EEG power is higher than 20 μV when measured at a Pz location.
34 . The positive susceptibility predictor of claim 30 , wherein said increased beta EEG power is higher than 25 μV when measured at a Cz location.
35 . The positive susceptibility predictor of claim 30 , wherein said increased beta EEG power is higher than 15 μV when measured at a Fz location.
36 . The positive susceptibility predictor of claim 30 , wherein said neuromodulation treatment is selected from the group consisting of transcranial magnetic stimulation, transcranial direct current stimulation, deep-brain stimulation, and neurofeedback.
37 . The positive susceptibility predictor of claim 30 , wherein said EEG dataset is measured from a location selected from the group consisting of F3, Fz, F4, Cz and Pz.
38 . The positive susceptibility predictor of claim 30 , wherein said neuromodulation treatment predicts a favorable treatment response in a patient with a psychiatric complaint selected from the group consisting of a major depressive disorder, bipolar disorder, dysthymia, and a depressive mood disorder.